EA201171188A1 - Профилактическое или терапевтическое средство против болезни сетчатки и способ профилактики или лечения болезни сетчатки с использованием jnk (c-jun-аминоконцевая киназа)-ингибиторного пептида, а также применение указанного пептида - Google Patents
Профилактическое или терапевтическое средство против болезни сетчатки и способ профилактики или лечения болезни сетчатки с использованием jnk (c-jun-аминоконцевая киназа)-ингибиторного пептида, а также применение указанного пептидаInfo
- Publication number
- EA201171188A1 EA201171188A1 EA201171188A EA201171188A EA201171188A1 EA 201171188 A1 EA201171188 A1 EA 201171188A1 EA 201171188 A EA201171188 A EA 201171188A EA 201171188 A EA201171188 A EA 201171188A EA 201171188 A1 EA201171188 A1 EA 201171188A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- seq
- jnk
- drug
- peptide
- jnk inhibitor
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000000069 prophylactic effect Effects 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 239000012825 JNK inhibitor Substances 0.000 abstract 3
- 229940118135 JNK inhibitor Drugs 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 3
- 208000017442 Retinal disease Diseases 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 150000008574 D-amino acids Chemical class 0.000 abstract 1
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000000608 photoreceptor cell Anatomy 0.000 abstract 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 abstract 1
- 230000000250 revascularization Effects 0.000 abstract 1
- 229940063673 spermidine Drugs 0.000 abstract 1
- 238000011200 topical administration Methods 0.000 abstract 1
- ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 abstract 1
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 abstract 1
- 210000004127 vitreous body Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Введение в стекловидное тело JNK-ингибиторного пептида длиной менее 150 аминокислот, который содержит по меньшей мере одну D-аминокислоту, а также (а) JNK-ингибиторную последовательность, по меньшей мере одну из SEQ ID NO: 1 и SEQ ID NO: 2, и (b) транспортную последовательность, по меньшей мере одну из SEQ ID NO: 3 и SEQ ID NO: 4, подавляет спермидин-индуцированное повреждение пигментного эпителия сетчатки, туникамицин-индуцированное повреждение фоторецепторных клеток и индуцированную лазером реваскуляризацию сосудистой оболочки глаза. Следовательно, JNK-ингибиторный пептид настоящего изобретения можно использовать для профилактики или лечения болезни сетчатки. На основе JNK-ингибиторного пептида можно разработать лекарственное средство и способ, позволяющие предотвращать или лечить болезнь сетчатки даже при местном введении лекарственного средства в глаз, и, кроме того, изобретение предлагает применение JNK-ингибиторного пептида в производстве указанного выше лекарственного средства.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009080992 | 2009-03-30 | ||
PCT/JP2010/055208 WO2010113753A1 (ja) | 2009-03-30 | 2010-03-25 | JNK(c-Junアミノ末端キナーゼ)阻害ペプチドを用いた網膜疾患の予防または治療剤、網膜疾患の予防または治療方法、ならびに、その使用 |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201171188A1 true EA201171188A1 (ru) | 2012-05-30 |
Family
ID=42828046
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201171188A EA201171188A1 (ru) | 2009-03-30 | 2010-03-25 | Профилактическое или терапевтическое средство против болезни сетчатки и способ профилактики или лечения болезни сетчатки с использованием jnk (c-jun-аминоконцевая киназа)-ингибиторного пептида, а также применение указанного пептида |
Country Status (8)
Country | Link |
---|---|
US (1) | US20120101046A1 (ru) |
EP (1) | EP2415478A4 (ru) |
JP (1) | JP2010254672A (ru) |
KR (1) | KR20120022721A (ru) |
CN (1) | CN102365093A (ru) |
CA (1) | CA2756864A1 (ru) |
EA (1) | EA201171188A1 (ru) |
WO (1) | WO2010113753A1 (ru) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007031098A1 (en) | 2005-09-12 | 2007-03-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
WO2009143864A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases |
WO2009143865A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
WO2010072228A1 (en) | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
WO2011160653A1 (en) * | 2010-06-21 | 2011-12-29 | Xigen S.A. | Novel jnk inhibitor molecules |
JP5857056B2 (ja) * | 2010-10-14 | 2016-02-10 | ザイジェン インフラメーション エルティーディー | 慢性又は非慢性の炎症性眼疾患を治療するためのjnkシグナル伝達経路の細胞透過性ペプチド阻害剤の使用 |
DK2902035T3 (en) * | 2010-10-14 | 2018-09-24 | Xigen Inflammation Ltd | METHODS FOR TREATING MUSCLE DYROPHY |
WO2013091670A1 (en) | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
WO2015197097A1 (en) | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
AU2014301631A1 (en) | 2013-06-26 | 2015-08-27 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases |
WO2014206427A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
WO2015197098A1 (en) * | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
WO2016055160A2 (en) * | 2014-10-08 | 2016-04-14 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
WO2014206426A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
CN106714821B (zh) * | 2014-06-26 | 2021-07-23 | 埃克西金炎症有限公司 | Jnk信号转导途径的细胞穿透肽抑制剂用于治疗多种疾病的新用途 |
AU2016258837B2 (en) * | 2015-05-01 | 2020-12-03 | Onl Therapeutics, Inc. | Peptide compositions and methods of use |
US20180170983A1 (en) * | 2015-06-26 | 2018-06-21 | Xigen Inflammation Ltd. | New Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Mild Cognitive Impairment |
AU2018445968A1 (en) * | 2018-10-19 | 2021-04-15 | Icm Co., Ltd. | Pharmaceutical composition for treating retinal diseases, comprising Nkx3.2 and fragment thereof as active ingredients |
CN109776656B (zh) * | 2019-01-11 | 2022-03-11 | 广州领晟医疗科技有限公司 | 一种用于抑制血管新生的多肽tin7n及其应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6610820B1 (en) * | 1999-10-12 | 2003-08-26 | University Of Lausanne | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US20030108539A1 (en) * | 2000-02-14 | 2003-06-12 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US20040082509A1 (en) * | 1999-10-12 | 2004-04-29 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
AU2003211931A1 (en) * | 2002-02-13 | 2003-09-04 | Takeda Chemical Industries, Ltd. | Jnk inhibitor |
US20040092568A1 (en) * | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods for the treatment, prevention and management of macular degeneration |
US20060094753A1 (en) | 2004-10-29 | 2006-05-04 | Alcon, Inc. | Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases |
US8080517B2 (en) * | 2005-09-12 | 2011-12-20 | Xigen Sa | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
WO2007031098A1 (en) | 2005-09-12 | 2007-03-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
-
2010
- 2010-03-25 EA EA201171188A patent/EA201171188A1/ru unknown
- 2010-03-25 EP EP10758526A patent/EP2415478A4/en not_active Withdrawn
- 2010-03-25 WO PCT/JP2010/055208 patent/WO2010113753A1/ja active Application Filing
- 2010-03-25 KR KR1020117021292A patent/KR20120022721A/ko not_active Application Discontinuation
- 2010-03-25 US US13/260,231 patent/US20120101046A1/en not_active Abandoned
- 2010-03-25 CN CN2010800142515A patent/CN102365093A/zh active Pending
- 2010-03-25 JP JP2010069759A patent/JP2010254672A/ja active Pending
- 2010-03-25 CA CA2756864A patent/CA2756864A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN102365093A (zh) | 2012-02-29 |
EP2415478A4 (en) | 2013-01-16 |
EP2415478A1 (en) | 2012-02-08 |
WO2010113753A1 (ja) | 2010-10-07 |
KR20120022721A (ko) | 2012-03-12 |
JP2010254672A (ja) | 2010-11-11 |
CA2756864A1 (en) | 2010-10-07 |
US20120101046A1 (en) | 2012-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201171188A1 (ru) | Профилактическое или терапевтическое средство против болезни сетчатки и способ профилактики или лечения болезни сетчатки с использованием jnk (c-jun-аминоконцевая киназа)-ингибиторного пептида, а также применение указанного пептида | |
NZ601868A (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
EA201000441A1 (ru) | Водные офтальмологические препараты | |
WO2007104541A3 (en) | Compositions and methods using serine protease inhibiting peptides for treating ophthalmic disorders | |
ES2688030T3 (es) | Péptidos permeables celulares inhibidores de la ruta de transducción de la señal JNK para su uso en el tratamiento de enfermedades oculares inflamatorias | |
RU2012140704A (ru) | Способ профилактики и/или лечения фиброза и/или помутнения роговицы (варианты), способ получения фармацевтической композиции для профилактики и/или лечения фиброза и/или помутнения роговицы и глазная фармацевтическая композиция | |
JP2019533722A5 (ru) | ||
DE602007013391D1 (de) | Cyclosporins zur behandlung und vorbeugung von augenerkrankungen | |
RU2008136324A (ru) | Желудочно-кишечный пролиферативный фактор и его применения | |
WO2011106573A3 (en) | Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae | |
EA200900662A1 (ru) | Лечение синдрома "сухого глаза" с помощью тестостерона и прогестагена | |
JP2013542919A5 (ru) | ||
NZ600544A (en) | Compositions and methods for the treatment of angiogenesis-related eye diseases | |
BRPI0607097B8 (pt) | uso de um peptídeo imunogênico para a fabricação de um medicamento para o tratamento, prevenção ou redução de infecção por papilomavírus | |
RU2013126581A (ru) | Мутанты стрептокиназы и их ковалентно модифицированные формы | |
FI3294345T3 (fi) | Tpp1-formulaatioita ja menetelmiä cln2-taudin hoitamiseksi | |
CY1113693T1 (el) | Φαρμακευτικες συνθεσεις και μεθοδοι για τον εμβολιασμο κατα της διαχυτης καντιντιασης και αλλων μολυσματικων παραγοντων | |
JP2012505154A5 (ru) | ||
UA112446C2 (uk) | Застосування омега-жирних кислот для лікування захворювання | |
EA200701017A1 (ru) | Применение рибозы-цистеина для лечения гипоксии | |
CO2021017664A2 (es) | Péptidos | |
MY178169A (en) | Topical ophthalmic peptide formulation | |
RU2011108486A (ru) | ПРИМЕНЕНИЕ ПРОИЗВОДНЫХ ПЕПТИДА Wnt5-a ДЛЯ ЛЕЧЕНИЯ МЕЛАНОМЫ И РАКА ЖЕЛУДКА | |
Chánez-Paredes et al. | The Arp2/3 inhibitory protein arpin is required for intestinal epithelial barrier integrity | |
RU2733432C1 (ru) | Лечение вирусного конъюнктивита с применением ранпирназы и/или амфиназы |